Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.

about

Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Is there a Chance to Promote Arteriogenesis by DPP4 Inhibitors Even in Type 2 Diabetes? A Critical Review

P2860

Q55401199-F5F714CC-6462-460F-8A3D-2D47F46A8E47 Q58579298-143615F5-8222-4AB9-9185-D85D89F5EB6E

P2860

Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.

Item

http://www.wikidata.org/entity/Q38662690

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.

@en

type

Item

label

Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.

@en

prefLabel

Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.

@en

P1476

Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.

@en

P2093

Jingbo Hu

http://www.w3.org/2001/XMLSchema#string

Minzhi Zhou

http://www.w3.org/2001/XMLSchema#string

Ping Zou

http://www.w3.org/2001/XMLSchema#string

Xiaojing Cao

http://www.w3.org/2001/XMLSchema#string

Xueying Tan

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

10-year follow-up of intensive glucose control in type 2 diabetes

Biology of incretins: GLP-1 and GIP

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials.

Effects of glucagon-like peptide-1 agents on left ventricular function: systematic review and meta-analysis.

P304

1083-1089

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13543784.2017.1360274

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28741970

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.

about

P2860

P2860

Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921